Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE-Care Trial: Empagliflozin in Gout Patients
NCT06674109Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gout and hyperuricemia comparing Empagliflozin 10mg with Placebo (2 arms). Primary endpoint: Serum Urate Change at 3 months. Started Jul 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06674109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674109.